Le N - Search Results

1

Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer: An Analysis of Outcomes Obtained With Oral Etoposide.

Kumar A, Le N, Santos J, Hoskins P. Kumar A, et al. Among authors: le n. Am J Clin Oncol. 2018 Apr;41(4):379-384. doi: 10.1097/COC.0000000000000281. Am J Clin Oncol. 2018. PMID: 26999277

2

Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse.

Hoskins PJ, Le N, Gascoyne RD, Klasa R, Shenkier T, O'Reilly S, Connors JM. Hoskins PJ, et al. Among authors: le n. Ann Oncol. 1997 Nov;8(11):1125-32. doi: 10.1023/a:1008263602334. Ann Oncol. 1997. PMID: 9426332 Free article.

3

Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.

Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, Zhang L. Rosin MP, et al. Among authors: le nd. Clin Cancer Res. 2000 Feb;6(2):357-62. Clin Cancer Res. 2000. PMID: 10690511

4

Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection.

Zhang L, Poh CF, Lam WL, Epstein JB, Cheng X, Zhang X, Priddy R, Lovas J, Le ND, Rosin MP. Zhang L, et al. Among authors: le nd. Oral Oncol. 2001 Sep;37(6):505-12. doi: 10.1016/s1368-8375(00)00140-8. Oral Oncol. 2001. PMID: 11435177

5

Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center.

Gill S, Shah A, Le N, Cook EF, Yoshida EM. Gill S, et al. Among authors: le n. J Clin Oncol. 2003 Jun 1;21(11):2070-6. doi: 10.1200/JCO.2003.11.054. J Clin Oncol. 2003. PMID: 12775731

6

Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer.

Hoskins PJ, Le N. Hoskins PJ, et al. Among authors: le n. Gynecol Oncol. 2005 Jun;97(3):862-9. doi: 10.1016/j.ygyno.2005.03.022. Gynecol Oncol. 2005. PMID: 15894355

7

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, Tinker AV; British Columbia Cancer Agency. Hoskins PJ, et al. Among authors: le n. Gynecol Oncol. 2008 Jan;108(1):58-62. doi: 10.1016/j.ygyno.2007.08.084. Epub 2007 Oct 23. Gynecol Oncol. 2008. PMID: 17935761

8

Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus.

Hoskins PJ, Le N. Hoskins PJ, et al. Among authors: le n. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1200-1. doi: 10.1111/j.1525-1438.2007.01187.x. Epub 2008 Jan 23. Int J Gynecol Cancer. 2008. PMID: 18217961

9

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. Gilks CB, et al. Among authors: le n. Hum Pathol. 2008 Aug;39(8):1239-51. doi: 10.1016/j.humpath.2008.01.003. Epub 2008 Jul 7. Hum Pathol. 2008. PMID: 18602670

10

Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience.

Mazgani M, Le N, Hoskins PJ; British Columbia Cancer Agency. Mazgani M, et al. Among authors: le n. Gynecol Oncol. 2008 Dec;111(3):474-7. doi: 10.1016/j.ygyno.2008.08.029. Epub 2008 Oct 16. Gynecol Oncol. 2008. PMID: 18929402

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,695 results

Search Page

Filters